

Peter Andreas Fasching

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9520251/publications.pdf>

Version: 2024-02-01

422
papers

41,100
citations

5261

83
h-index

3181

186
g-index

465
all docs

465
docs citations

465
times ranked

34591
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Genetic variants in the genes of the sex steroid hormone metabolism and depressive symptoms during and after pregnancy. Archives of Gynecology and Obstetrics, 2023, 307, 1763-1770. | 0.8 | 2 |
| 2 | Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial. Journal of Medical Internet Research, 2022, 24, e16128. | 2.1 | 6 |
| 3 | MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 855-871. | 1.4 | 8 |
| 4 | Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. European Journal of Cancer, 2022, 160, 100-111. | 1.3 | 12 |
| 5 | Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65. | 2.0 | 6 |
| 6 | Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2. | 2.2 | 15 |
| 7 | ABC6 Consensus: Assessment by a Group of German Experts. Breast Care, 2022, 17, 90-100. | 0.8 | 6 |
| 8 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncology, 2022, 8, e216744. | 3.4 | 51 |
| 9 | Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. Cancers, 2022, 14, 521. | 1.7 | 12 |
| 10 | Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. Clinical Cancer Research, 2022, 28, 1854-1862. | 3.2 | 5 |
| 11 | OUP accepted manuscript. Human Molecular Genetics, 2022, , . | 1.4 | 1 |
| 12 | Update Breast Cancer 2021 Part 4 "Prevention and Early Stages. Geburtshilfe Und Frauenheilkunde, 2022, 82, 206-214. | 0.8 | 4 |
| 13 | Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2022, 386, 556-567. | 13.9 | 444 |
| 14 | Update Breast Cancer 2021 Part 5 "Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2022, 82, 215-225. | 0.8 | 6 |
| 15 | Prevalence of SARS-CoV-2 in Pregnant Women Assessed by RT-PCR in Franconia, Germany: First Results of the SCENARIO Study (SARS-CoV-2 prevalence in pregnancy and at birth in Franconia). Geburtshilfe Und Frauenheilkunde, 2022, 82, 226-234. | 0.8 | 6 |
| 16 | Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. Cancer Research, 2022, 82, PD8-01-PD8-01. | 0.4 | 4 |
| 17 | The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. British Journal of Cancer, 2022, 126, 1715-1724. | 2.9 | 14 |
| 18 | Abstract PD13-06: Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study. Cancer Research, 2022, 82, PD13-06-PD13-06. | 0.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Heart Rate Measurement Accuracy of Fitbit Charge 4 and Samsung Galaxy Watch Active2: Device Evaluation Study. JMIR Formative Research, 2022, 6, e33635. | 0.7 | 19 |
| 20 | MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. Cancers, 2022, 14, 1721. | 1.7 | 5 |
| 21 | AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. Breast Care, 2022, 17, 421-429. | 0.8 | 9 |
| 22 | Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptorâ€“positive, HER2-negative, untreated early breast cancer (ER+/HER2â€“ eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.. Journal of Clinical Oncology, 2022, 40, 589-589. | 0.8 | 20 |
| 23 | Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics â€“ A retrospective analysis of a real world registry. European Journal of Cancer, 2022, 172, 13-21. | 1.3 | 1 |
| 24 | Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. Clinical Cancer Research, 2022, 28, 3342-3355. | 3.2 | 3 |
| 25 | Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228. | 1.1 | 12 |
| 26 | Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology, 2021, 34, 194-206. | 2.9 | 21 |
| 27 | Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Breast Care, 2021, 16, 254-262. | 0.8 | 0 |
| 28 | Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319. | 2.3 | 35 |
| 29 | Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center Regarding Consensus between the First and Second Opinion and Conformity with the Guidelines. Breast Care, 2021, 16, 291-298. | 0.8 | 2 |
| 30 | Genetic variations in estrogen and progesterone pathway genes in preeclampsia patients and controls in Bavaria. Archives of Gynecology and Obstetrics, 2021, 303, 897-904. | 0.8 | 2 |
| 31 | The association between prenatal alcohol consumption and preschool child stress system disturbance. Developmental Psychobiology, 2021, 63, 687-697. | 0.9 | 10 |
| 32 | Genetic variants in the glucocorticoid pathway genes and birth weight. Archives of Gynecology and Obstetrics, 2021, 303, 427-434. | 0.8 | 1 |
| 33 | Prenatal Alcohol Exposure and the Facial Phenotype in Adolescents: A Study Based on Meconium Ethyl Glucuronide. Brain Sciences, 2021, 11, 154. | 1.1 | 7 |
| 34 | CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854. | 2.9 | 5 |
| 35 | Active Participation, Mindâ€“Body Stabilization, and Coping Strategies with Integrative Medicine in Breast Cancer Patients. Integrative Cancer Therapies, 2021, 20, 153473542199010. | 0.8 | 1 |
| 36 | Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. Breast Care, 2021, 16, 108-114. | 0.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078. | 5.8 | 19 |
| 38 | Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2584-2591. | 3.2 | 27 |
| 39 | Abstract PS2-02: Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. <i>Cancer Research</i> , 2021, 81, PS2-02-PS2-02. | 0.4 | 1 |
| 40 | Breast Cancer Risk Genes " Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021, 384, 428-439. | 13.9 | 532 |
| 41 | Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry" Comparison of Three Different GPA Prognostic Scores. <i>Cancers</i> , 2021, 13, 844. | 1.7 | 7 |
| 42 | Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2021, 145, 44-52. | 1.3 | 5 |
| 43 | Update Breast Cancer 2020 Part 5 " Moving Therapies From Advanced to Early Breast Cancer Patients. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 469-480. | 0.8 | 6 |
| 44 | Associations between Genetically Predicted Circulating Protein Concentrations and Endometrial Cancer Risk. <i>Cancers</i> , 2021, 13, 2088. | 1.7 | 10 |
| 45 | Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 573. | 3.4 | 217 |
| 46 | Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?. <i>Cancers</i> , 2021, 13, 2370. | 1.7 | 4 |
| 47 | Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer " Association With Patient and Disease Characteristics and Effect on Prognosis. <i>Journal of Clinical Oncology</i> , 2021, 39, 1619-1630. | 0.8 | 39 |
| 48 | Update Breast Cancer 2021 Part 2 " Advanced Stages, Long-Term Consequences and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 539-548. | 0.8 | 6 |
| 49 | Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 637-653. | 0.8 | 5 |
| 50 | Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.. <i>Journal of Clinical Oncology</i> , 2021, 39, 519-519. | 0.8 | 2 |
| 51 | Update Breast Cancer 2021 Part 1 " Prevention and Early Stages. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 526-538. | 0.8 | 10 |
| 52 | Association of genomic variants at <i>PAX8</i> and <i>PBX2</i> with cervical cancer risk. <i>International Journal of Cancer</i> , 2021, 149, 893-900. | 2.3 | 7 |
| 53 | Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors " An analysis of 2765 patients from neoadjuvant clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 159-170. | 1.3 | 41 |
| 54 | Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1669-1680. | 1.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Patterns and Trends of Herbal Medicine Use among Patients with Gynecologic Cancer. Geburtshilfe Und Frauenheilkunde, 2021, 81, 699-707. | 0.8 | 9 |
| 56 | Update Breast Cancer 2021 Part 3 – Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. Geburtshilfe Und Frauenheilkunde, 2021, 81, 654-665. | 0.8 | 4 |
| 57 | Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203. | 2.6 | 6 |
| 58 | Association of Prenatal Alcohol Exposure and Prenatal Maternal Depression with Offspring Low-Grade Inflammation in Early Adolescence. International Journal of Environmental Research and Public Health, 2021, 18, 7920. | 1.2 | 6 |
| 59 | Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. Human Genetics, 2021, 140, 1353-1365. | 1.8 | 18 |
| 60 | Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. European Journal of Cancer, 2021, 152, 68-77. | 1.3 | 18 |
| 61 | Comparison of methods for isolation and quantification of circulating cell-free DNA from patients with endometriosis. Reproductive BioMedicine Online, 2021, 43, 788-798. | 1.1 | 2 |
| 62 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86. | 2.2 | 7 |
| 63 | Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncology, The, 2021, 22, 1151-1161. | 5.1 | 248 |
| 64 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145. | 2.9 | 9 |
| 65 | Comprehensive characterization of endometriosis patients and disease patterns in a large clinical cohort. Archives of Gynecology and Obstetrics, 2021, , 1. | 0.8 | 2 |
| 66 | Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. European Journal of Cancer, 2021, 155, 1-12. | 1.3 | 39 |
| 67 | Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. European Journal of Cancer, 2021, 154, 128-137. | 1.3 | 24 |
| 68 | Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer – A Europe-Wide External Quality Assessment. Cancers, 2021, 13, 4718. | 1.7 | 6 |
| 69 | Mammographic density and prognosis in primary breast cancer patients. Breast, 2021, 59, 51-57. | 0.9 | 13 |
| 70 | Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642. | 1.1 | 19 |
| 71 | AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. Breast Care, 2021, 16, 228-235. | 0.8 | 20 |
| 72 | AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care, 2021, 16, 214-227. | 0.8 | 51 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021, 11, 19787. | 1.6 | 2 |
| 74 | A careful reassessment of anthracycline use in curable breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 134. | 2.3 | 25 |
| 75 | Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. <i>Cancers</i> , 2021, 13, 5577. | 1.7 | 5 |
| 76 | Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement. <i>Cancers</i> , 2021, 13, 5643. | 1.7 | 16 |
| 77 | Comparison of C-Reactive Protein in Dried Blood Spots and Saliva of Healthy Adolescents. <i>Frontiers in Immunology</i> , 2021, 12, 795580. | 2.2 | 3 |
| 78 | Update Mammakarzinom 2021 Teil 1 – Prävention und frühe Krankheitsstadien. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2021, 18, 377-390. | 0.0 | 0 |
| 79 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73. | 9.4 | 120 |
| 80 | Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 289-294. | 0.8 | 5 |
| 81 | Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 514-524. | 13.9 | 482 |
| 82 | Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2020, 26, 6523-6534. | 3.2 | 16 |
| 83 | Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095793. | 1.4 | 9 |
| 84 | Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. <i>Cancers</i> , 2020, 12, 2787. | 1.7 | 12 |
| 85 | HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment. <i>Scientific Reports</i> , 2020, 10, 15750. | 1.6 | 15 |
| 86 | PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer. <i>Cancers</i> , 2020, 12, 2742. | 1.7 | 4 |
| 87 | Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. <i>Breast</i> , 2020, 54, 148-154. | 0.9 | 25 |
| 88 | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. <i>Cancers</i> , 2020, 12, 3021. | 1.7 | 6 |
| 89 | Does anxiety impact the neural processing of child faces in mothers of school-aged children? An ERP study using an emotional Go/NoGo task. <i>Social Neuroscience</i> , 2020, 15, 530-543. | 0.7 | 2 |
| 90 | Update Breast Cancer 2020 Part 3 – Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1105-1114. | 0.8 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Update Breast Cancer 2020 Part 4 â€“ Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1115-1122. | 0.8 | 11 |
| 92 | HLA-J, a Non-Pseudogene as a New Prognostic Marker for Therapy Response and Survival in Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1123-1133. | 0.8 | 13 |
| 93 | Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1134-1142. | 0.8 | 4 |
| 94 | Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC Cancer, 2020, 20, 1091. | 1.1 | 1 |
| 95 | Breast MRI texture analysis for prediction of BRCA-associated genetic risk. BMC Medical Imaging, 2020, 20, 86. | 1.4 | 8 |
| 96 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848. | 2.6 | 39 |
| 97 | Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer â€“ Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast, 2020, 54, 88-95. | 0.9 | 34 |
| 98 | Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients. Breast Cancer Research and Treatment, 2020, 184, 311-324. | 1.1 | 10 |
| 99 | Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. Cancer Research, 2020, 80, 5427-5434. | 0.4 | 77 |
| 100 | Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancerâ€”results from the randomized phase III SUCCESS-A trial. Breast Cancer Research, 2020, 22, 111. | 2.2 | 15 |
| 101 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581. | 9.4 | 265 |
| 102 | Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (ProTYPE). Clinical Cancer Research, 2020, 26, 5411-5423. | 3.2 | 43 |
| 103 | International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus â€“ Assessment by a German Group of Experts. Breast Care, 2020, 15, 82-95. | 0.8 | 25 |
| 104 | Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer. JAMA Oncology, 2020, 6, 744. | 3.4 | 42 |
| 105 | Update Breast Cancer 2020 Part 1 â€“ Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Und Frauenheilkunde, 2020, 80, 277-287. | 0.8 | 16 |
| 106 | RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women. Scientific Reports, 2020, 10, 5171. | 1.6 | 5 |
| 107 | Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. European Journal of Cancer, 2020, 130, 92-101. | 1.3 | 26 |
| 108 | A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. Clinical Cancer Research, 2020, 26, 1896-1904. | 3.2 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. <i>Breast Care</i> , 2020, 15, 294-309. | 0.8 | 47 |
| 110 | Association of genomic variants at the human leukocyte antigen locus with cervical cancer risk, HPV status and gene expression levels. <i>International Journal of Cancer</i> , 2020, 147, 2458-2468. | 2.3 | 12 |
| 111 | ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 588-600. | 0.8 | 1 |
| 112 | Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 810-821. | 13.9 | 1,542 |
| 113 | Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468. | 0.6 | 32 |
| 114 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020, 11, 312. | 5.8 | 30 |
| 115 | Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 423-434. | 1.1 | 14 |
| 116 | Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 391-398. | 0.8 | 12 |
| 117 | Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor β . <i>Clinical Cancer Research</i> , 2020, 26, 2986-2996. | 3.2 | 17 |
| 118 | A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4242-4249. | 3.2 | 29 |
| 119 | Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1096-1104. | 2.3 | 33 |
| 120 | A phase II single-arm, multicenter, open-label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple-negative breast cancer: Neoimmunoblast. <i>Journal of Clinical Oncology</i> , 2020, 38, e12647-e12647. | 0.8 | 0 |
| 121 | Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019, 79, 505-517. | 0.4 | 49 |
| 122 | Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 206-211. | 1.2 | 18 |
| 123 | Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial. <i>International Journal of Cancer</i> , 2019, 144, 877-885. | 2.3 | 31 |
| 124 | Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. <i>Fertility and Sterility</i> , 2019, 112, 731-739.e1. | 0.5 | 10 |
| 125 | Response to Di Cosimo, Torri, and Porcu. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1234-1235. | 3.0 | 1 |
| 126 | Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1079-1089. | 0.8 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Update Breast Cancer 2019 Part 5 â€“ Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1090-1099. | 0.8 | 16 |
| 128 | Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524. | 1.6 | 5 |
| 129 | AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care, 2019, 14, 224-245. | 0.8 | 72 |
| 130 | Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431. | 5.8 | 88 |
| 131 | Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. Breast, 2019, 44, 81-89. | 0.9 | 8 |
| 132 | Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. International Journal of Cancer, 2019, 145, 857-868. | 2.3 | 12 |
| 133 | A Phase II Randomized Study of Neoadjuvant Letrozole Plus Apelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clinical Cancer Research, 2019, 25, 2975-2987. | 3.2 | 76 |
| 134 | Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) â€“ Recommendations for Daily Routine Practice. Geburtshilfe Und Frauenheilkunde, 2019, 79, 605-617. | 0.8 | 28 |
| 135 | Salivary and hair cortisol as biomarkers of emotional and behavioral symptoms in 6â€“9-year old children. Physiology and Behavior, 2019, 209, 112584. | 1.0 | 18 |
| 136 | Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. BMC Cancer, 2019, 19, 611. | 1.1 | 5 |
| 137 | Update Breast Cancer 2019 Part 1 â€“ Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 256-267. | 0.8 | 17 |
| 138 | Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. Journal of Clinical Oncology, 2019, 37, 2206-2216. | 0.8 | 152 |
| 139 | Update Breast Cancer 2019 Part 3 â€“ Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Und Frauenheilkunde, 2019, 79, 470-482. | 0.8 | 26 |
| 140 | Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIIIâ€“IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Research and Treatment, 2019, 176, 557-568. | 1.1 | 10 |
| 141 | Update Breast Cancer 2019 Part 2 â€“ Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe Und Frauenheilkunde, 2019, 79, 268-280. | 0.8 | 21 |
| 142 | Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Research, 2019, 21, 60. | 2.2 | 16 |
| 143 | NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBC 69â€“GeparSepto. Journal of Clinical Oncology, 2019, 37, 2226-2234. | 0.8 | 95 |
| 144 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741. | 5.8 | 90 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 2114-2121. | 2.3 | 6 |
| 146 | Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 617-625. | 1.1 | 35 |
| 147 | Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3986-3995. | 3.2 | 32 |
| 148 | Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657. | 2.9 | 52 |
| 149 | Translational highlights in breast cancer research and treatment: recent developments with clinical impact. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019, 31, 67-75. | 0.9 | 16 |
| 150 | Neoadjuvant Treatment of HER2-Positive Breast Cancer – A Review. , 2019, , 95-106. | | 0 |
| 151 | Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study. <i>Breast Care</i> , 2019, 14, 41-47. | 0.8 | 5 |
| 152 | Prediction and clinical utility of a contralateral breast cancer risk model. <i>Breast Cancer Research</i> , 2019, 21, 144. | 2.2 | 24 |
| 153 | Translational Highlights in Breast and Ovarian Cancer 2019 – “Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1309-1319. | 0.8 | 11 |
| 154 | Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2019, 21, 142. | 2.2 | 21 |
| 155 | Awareness of breast cancer incidence and risk factors among healthy women in Germany: an update after 10 years. <i>European Journal of Cancer Prevention</i> , 2019, 28, 515-521. | 0.6 | 12 |
| 156 | Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. <i>Cancers</i> , 2019, 11, 10. | 1.7 | 43 |
| 157 | A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO). <i>Clinical Cancer Research</i> , 2019, 25, 2717-2724. | 3.2 | 102 |
| 158 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34. | 2.6 | 711 |
| 159 | Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 453-461. | 1.1 | 15 |
| 160 | Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 319-328. | 1.1 | 40 |
| 161 | Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto – GBG 84): A randomised phase III trial. <i>European Journal of Cancer</i> , 2019, 106, 181-192. | 1.3 | 84 |
| 162 | The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. <i>Journal of Bone Oncology</i> , 2019, 14, 100199. | 1.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 163 | Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medicine, 2019, 380, 617-628. | 13.9 | 1,610 |
| 164 | NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).. Journal of Clinical Oncology, 2019, 37, TPS597-TPS597. | 0.8 | 44 |
| 165 | An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer) Tj ETQq1 1 0.784314 rgBT /Overlock Breast Cancer: Reliability Study. Journal of Medical Internet Research, 2019, 21, e10004. | 2.1 | 29 |
| 166 | MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320. | 1.4 | 22 |
| 167 | TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. Breast Care, 2018, 13, 8-14. | 0.8 | 32 |
| 168 | Digit ratio (2D:4D) and behavioral symptoms in primary-school aged boys. Early Human Development, 2018, 119, 1-7. | 0.8 | 18 |
| 169 | Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129. | 2.9 | 15 |
| 170 | Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Medicine, 2018, 7, 1978-1987. | 1.3 | 62 |
| 171 | Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers. Geburtshilfe Und Frauenheilkunde, 2018, 78, 237-245. | 0.8 | 20 |
| 172 | Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?. Lancet Oncology, The, 2018, 19, 150-151. | 5.1 | 12 |
| 173 | Breast cancer patients' satisfaction with individual therapy goals and treatment in a standardized integrative medicine consultancy service. Archives of Gynecology and Obstetrics, 2018, 298, 147-156. | 0.8 | 7 |
| 174 | Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. BMC Cancer, 2018, 18, 204. | 1.1 | 30 |
| 175 | BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. Breast Cancer Research and Treatment, 2018, 171, 85-94. | 1.1 | 56 |
| 176 | Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. Clinical Breast Cancer, 2018, 18, 175-183. | 1.1 | 21 |
| 177 | Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Und Frauenheilkunde, 2018, 78, 246-259. | 0.8 | 23 |
| 178 | Initial clinical results with a fusion prototype for mammography and three-dimensional ultrasound with a standard mammography system and a standard ultrasound probe. Acta Radiologica, 2018, 59, 1406-1413. | 0.5 | 10 |
| 179 | Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. Breast, 2018, 37, 42-51. | 0.9 | 54 |
| 180 | Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Research and Treatment, 2018, 167, 59-71. | 1.1 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Effects of prenatal alcohol consumption on cognitive development and <scp>ADHD</scp>-related behaviour in primary-school age: a multilevel study based on meconium ethyl glucuronide. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2018, 59, 110-118. | 3.1 | 27 |
| 182 | Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast, 2018, 37, 154-160. | 0.9 | 56 |
| 183 | Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncology, The, 2018, 19, 40-50. | 5.1 | 1,327 |
| 184 | BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. Journal of Clinical Oncology, 2018, 36, 2281-2287. | 0.8 | 86 |
| 185 | Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. Journal of Clinical Oncology, 2018, 36, 2465-2472. | 0.8 | 704 |
| 186 | Supportive Infusions in Integrative Breast and Gynecological Oncology - Report on Patients' Satisfaction and Self-reported Effects and Side Effects. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1129-1137. | 0.8 | 1 |
| 187 | ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro. BMC Cancer, 2018, 18, 1273. | 1.1 | 26 |
| 188 | Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1119-1128. | 0.8 | 3 |
| 189 | Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1110-1118. | 0.8 | 8 |
| 190 | Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria. BMC Cancer, 2018, 18, 926. | 1.1 | 16 |
| 191 | Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. BMC Cancer, 2018, 18, 1051. | 1.1 | 59 |
| 192 | Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 927-948. | 0.8 | 59 |
| 193 | Predicting attention deficit hyperactivity disorder using pregnancy and birth characteristics. Archives of Gynecology and Obstetrics, 2018, 298, 889-895. | 0.8 | 28 |
| 194 | Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. Pharmacogenetics and Genomics, 2018, 28, 147-152. | 0.7 | 4 |
| 195 | The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer. Breast Cancer Research and Treatment, 2018, 171, 747-758. | 1.1 | 12 |
| 196 | Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261. | 1.3 | 70 |
| 197 | Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. Journal of the National Cancer Institute, 2018, 110, 855-862. | 3.0 | 225 |
| 198 | Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients. Frontiers in Pharmacology, 2018, 9, 158. | 1.6 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430. | 0.4 | 54 |
| 200 | Prenatal Alcohol Exposure Is Associated With Adverse Cognitive Effects and Distinct Whole-Genome DNA Methylation Patterns in Primary School Children. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 125. | 1.0 | 19 |
| 201 | Self-reported Improvement in Side Effects and Quality of Life With Integrative Medicine in Breast Cancer Patients. <i>Integrative Cancer Therapies</i> , 2018, 17, 941-951. | 0.8 | 9 |
| 202 | Identification of nine new susceptibility loci for endometrial cancer. <i>Nature Communications</i> , 2018, 9, 3166. | 5.8 | 178 |
| 203 | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473. | 1.8 | 3 |
| 204 | Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 707-714. | 0.8 | 3 |
| 205 | Risk, Prediction and Prevention of Hereditary Breast Cancer – Large-Scale Genomic Studies in Times of Big and Smart Data. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 481-492. | 0.8 | 38 |
| 206 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978. | 9.4 | 184 |
| 207 | Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).. <i>Journal of Clinical Oncology</i> , 2018, 36, 522-522. | 0.8 | 17 |
| 208 | Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 279-285. | 1.1 | 10 |
| 209 | Genetic risk factors for ovarian cancer and their role for endometriosis risk. <i>Gynecologic Oncology</i> , 2017, 145, 142-147. | 0.6 | 24 |
| 210 | Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. <i>Nature Genetics</i> , 2017, 49, 834-841. | 9.4 | 426 |
| 211 | Correlation of mammographic density and serum calcium levels in patients with primary breast cancer. <i>Cancer Medicine</i> , 2017, 6, 1473-1481. | 1.3 | 13 |
| 212 | Semi-automated De-identification of German Content Sensitive Reports for Big Data Analytics. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2017, 189, 661-671. | 0.7 | 4 |
| 213 | Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1239-1245. | 0.8 | 42 |
| 214 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691. | 9.4 | 356 |
| 215 | Semi-automated delineation of breast cancer tumors and subsequent materialization using three-dimensional printing (rapid prototyping). <i>Journal of Surgical Oncology</i> , 2017, 115, 238-242. | 0.8 | 12 |
| 216 | Association between mammographic density and pregnancies relative to age and BMI: a breast cancer case-only analysis. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 701-708. | 1.1 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 217 | Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290. | 3.4 | 260 |
| 218 | Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94. | 13.7 | 1,099 |
| 219 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778. | 9.4 | 289 |
| 220 | Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 870-878. | 0.8 | 24 |
| 221 | History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1470-1473. | 1.1 | 10 |
| 222 | Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. <i>International Journal of Cancer</i> , 2017, 141, 1830-1840. | 2.3 | 20 |
| 223 | Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1378. | 3.4 | 300 |
| 224 | Children of Prenatally Depressed Mothers: Externalizing and Internalizing Symptoms are Accompanied by Reductions in Specific Social-Emotional Competencies. <i>Journal of Child and Family Studies</i> , 2017, 26, 3135-3144. | 0.7 | 19 |
| 225 | Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 633-644. | 0.8 | 28 |
| 226 | Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women. <i>Nature Communications</i> , 2017, 8, 1632. | 5.8 | 18 |
| 227 | Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 667-678. | 0.8 | 21 |
| 228 | Updates on the role of receptor activator of nuclear factor κ B/receptor activator of nuclear factor κ B ligand/osteoprotegerin pathway in breast cancer risk and treatment. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017, 29, 4-11. | 0.9 | 10 |
| 229 | Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. <i>Integrative Cancer Therapies</i> , 2017, 16, 165-175. | 0.8 | 22 |
| 230 | Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. <i>International Journal of Cancer</i> , 2017, 140, 95-102. | 2.3 | 99 |
| 231 | Update Breast Cancer 2017 – Implementation of Novel Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1281-1290. | 0.8 | 19 |
| 232 | Using automated texture features to determine the probability for masking of a tumor on mammography, but not ultrasound. <i>European Journal of Medical Research</i> , 2017, 22, 30. | 0.9 | 6 |
| 233 | Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-12. | 1.5 | 9 |
| 234 | TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. <i>Oncotarget</i> , 2017, 8, 18381-18398. | 0.8 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. <i>Oncotarget</i> , 2017, 8, 64670-64684. | 0.8 | 7 |
| 236 | Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. <i>Anticancer Research</i> , 2017, 37, 3117-3128. | 0.5 | 14 |
| 237 | Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients. <i>JMIR Cancer</i> , 2017, 3, e11. | 0.9 | 38 |
| 238 | Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. <i>Journal of Medical Internet Research</i> , 2017, 19, e322. | 2.1 | 48 |
| 239 | Risikoadaptierte Diagnostik und Therapie. , 2017, , 43-53. | | 0 |
| 240 | Zukünftige Entwicklungen in der Bildgebung. , 2017, , 201-218. | | 0 |
| 241 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. <i>PLoS ONE</i> , 2016, 11, e0160316. | 1.1 | 12 |
| 242 | Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895. | 0.9 | 71 |
| 243 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 1303-1317. | 2.3 | 51 |
| 244 | Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164. | 2.9 | 230 |
| 245 | Neoadjuvant Treatment of Breast Cancer - Advances and Limitations. <i>Breast Care</i> , 2016, 11, 313-314. | 0.8 | 12 |
| 246 | Patient survival and tumor characteristics associated with CHEK2:p.I157T â€“ findings from the Breast Cancer Association Consortium. <i>Breast Cancer Research</i> , 2016, 18, 98. | 2.2 | 39 |
| 247 | Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. <i>Breast Care</i> , 2016, 11, 315-322. | 0.8 | 6 |
| 248 | The Clinical Data Intelligence Project. <i>Informatik-Spektrum</i> , 2016, 39, 290-300. | 1.0 | 14 |
| 249 | Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756. | 1.8 | 19 |
| 250 | Genetic predisposition to ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2016, 18, 22. | 2.2 | 43 |
| 251 | Five endometrial cancer risk loci identified through genome-wide association analysis. <i>Nature Genetics</i> , 2016, 48, 667-674. | 9.4 | 77 |
| 252 | Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630. | 0.9 | 111 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. <i>American Journal of Human Genetics</i> , 2016, 99, 903-911. | 2.6 | 59 |
| 254 | Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1503-1510. | 1.1 | 64 |
| 255 | Did you drink alcohol during pregnancy? Inaccuracy and discontinuity of women's self-reports: On the way to establish meconium ethyl glucuronide (EtG) as a biomarker for alcohol consumption during pregnancy. <i>Alcohol</i> , 2016, 54, 39-44. | 0.8 | 55 |
| 256 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067. | 7.7 | 157 |
| 257 | Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography. <i>International Journal of Cancer</i> , 2016, 139, 1967-1974. | 2.3 | 19 |
| 258 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375. | 5.8 | 93 |
| 259 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675. | 5.8 | 78 |
| 260 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for <i>CH</i> <i>EK</i> <i>2</i> <i>*1100delC</i> Carriers. <i>Journal of Clinical Oncology</i> , 2016, 34, 2750-2760. | 0.8 | 152 |
| 261 | Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 59-65. | 1.1 | 27 |
| 262 | Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2675-2683. | 3.2 | 41 |
| 263 | CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, 77-91. | 1.6 | 62 |
| 264 | No evidence that protein truncating variants in <i>BRIP1</i> are associated with breast cancer risk: implications for gene panel testing. <i>Journal of Medical Genetics</i> , 2016, 53, 298-309. | 1.5 | 94 |
| 265 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate <i>ESR1</i> , <i>RMND1</i> and <i>CCDC170</i> . <i>Nature Genetics</i> , 2016, 48, 374-386. | 9.4 | 125 |
| 266 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401. | 0.6 | 18 |
| 267 | A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA.. <i>Journal of Clinical Oncology</i> . 2016. 34. TPS1096-TPS1096. | 0.8 | 7 |
| 268 | Assessment of variation in immunosuppressive pathway genes reveals <i>TGFBR2</i> to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110. | 0.8 | 5 |
| 269 | Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394. | 0.8 | 13 |
| 270 | Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 6353-6368. | 0.8 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Investigation of gene–environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. <i>International Journal of Cancer</i> , 2015, 136, E685-96. | 2.3 | 34 |
| 272 | Endometriosis as a risk factor for ovarian or endometrial cancer – results of a hospital-based case–control study. <i>BMC Cancer</i> , 2015, 15, 751. | 1.1 | 25 |
| 273 | Epithelial–Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697. | 0.6 | 22 |
| 274 | Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015, 17, 58. | 2.2 | 26 |
| 275 | A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density. <i>Breast Cancer Research</i> , 2015, 17, 110. | 2.2 | 19 |
| 276 | Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQ into study. <i>International Journal of Cancer</i> , 2015, 137, 2981-2988. | 2.3 | 31 |
| 277 | Association of molecular subtypes with breast cancer risk factors. <i>European Journal of Cancer Prevention</i> , 2015, 24, 484-490. | 0.6 | 14 |
| 278 | Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015, 10, e0128106. | 1.1 | 44 |
| 279 | SNP-SNP interaction analysis of NF- κ B signaling pathway on breast cancer survival. <i>Oncotarget</i> , 2015, 6, 37979-37994. | 0.8 | 20 |
| 280 | Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. <i>Journal of the National Cancer Institute</i> , 2015, 107, . | 3.0 | 428 |
| 281 | Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 304-311. | 0.8 | 521 |
| 282 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. <i>Human Molecular Genetics</i> , 2015, 24, 2966-2984. | 1.4 | 40 |
| 283 | Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20. | 2.6 | 76 |
| 284 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171. | 9.4 | 221 |
| 285 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015, 47, 373-380. | 9.4 | 513 |
| 286 | The Contributions of Breast Density and Common Genetic Variation to Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2015, 107, . | 3.0 | 174 |
| 287 | Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584. | 1.1 | 28 |
| 288 | Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015, 21, 5264-5276. | 3.2 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34. | 2.6 | 37 |
| 290 | Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, . | 3.0 | 56 |
| 291 | Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548. | 0.6 | 15 |
| 292 | Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Human Genetics, 2015, 134, 231-245. | 1.8 | 34 |
| 293 | Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. Cancer Research, 2015, 75, 2457-2467. | 0.4 | 55 |
| 294 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 2015, 47, 1294-1303. | 9.4 | 357 |
| 295 | Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353. | 1.3 | 24 |
| 296 | Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases. BMC Cancer, 2015, 15, 587. | 1.1 | 19 |
| 297 | Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964. | 1.4 | 68 |
| 298 | The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Research, 2015, 17, 129. | 2.2 | 93 |
| 299 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219. | 3.0 | 99 |
| 300 | Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. Endocrine-Related Cancer, 2015, 22, 851-861. | 1.6 | 25 |
| 301 | Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691. | 1.1 | 24 |
| 302 | Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 671-676. | 1.1 | 82 |
| 303 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298. | 1.4 | 38 |
| 304 | Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics, 2015, 24, 1478-1492. | 1.4 | 50 |
| 305 | The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget, 2015, 6, 7390-7407. | 0.8 | 15 |
| 306 | Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, . | 0.3 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 307 | MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973. | 1.1 | 49 |
| 308 | Biomarkers in Women's Cancers, Gynecology, and Obstetrics. BioMed Research International, 2014, 2014, 1-2. | 0.9 | 2 |
| 309 | Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast Cancer Research and Treatment, 2014, 148, 143-151. | 1.1 | 45 |
| 310 | Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285. | 1.5 | 39 |
| 311 | Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients. Journal of the National Cancer Institute, 2014, 106, . | 3.0 | 493 |
| 312 | Genetic Variants in the Genes of the Stress Hormone Signalling Pathway and Depressive Symptoms during and after Pregnancy. BioMed Research International, 2014, 2014, 1-8. | 0.9 | 21 |
| 313 | Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma. BioMed Research International, 2014, 2014, 1-9. | 0.9 | 38 |
| 314 | Meconium Indicators of Maternal Alcohol Abuse during Pregnancy and Association with Patient Characteristics. BioMed Research International, 2014, 2014, 1-11. | 0.9 | 27 |
| 315 | Variation in NF- κ B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427. | 1.1 | 13 |
| 316 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nature Communications, 2014, 5, 4051. | 5.8 | 16 |
| 317 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111. | 1.4 | 53 |
| 318 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419. | 2.2 | 97 |
| 319 | Assessment of breast volume changes during human pregnancy using a three-dimensional surface assessment technique in the prospective CGATE study. European Journal of Cancer Prevention, 2014, 23, 151-157. | 0.6 | 12 |
| 320 | Polymorphisms in the <i>RANK/RANKL</i> Genes and Their Effect on Bone Specific Prognosis in Breast Cancer Patients. BioMed Research International, 2014, 2014, 1-7. | 0.9 | 18 |
| 321 | <i>CYP2B6</i> *6 is associated with increased breast cancer risk. International Journal of Cancer, 2014, 134, 426-430. | 2.3 | 24 |
| 322 | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, The, 2014, 384, 164-172. | 6.3 | 3,224 |
| 323 | FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC Cancer, 2014, 14, 66. | 1.1 | 19 |
| 324 | Comprehensive visualization of paresthesia in breast cancer survivors. Archives of Gynecology and Obstetrics, 2014, 290, 135-141. | 0.8 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. <i>Human Genetics</i> , 2014, 133, 481-497. | 1.8 | 23 |
| 326 | HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 193-203. | 1.1 | 31 |
| 327 | Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene-Environment Interactions. <i>Genetic Epidemiology</i> , 2014, 38, 84-93. | 0.6 | 28 |
| 328 | Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. <i>Carcinogenesis</i> , 2014, 35, 1012-1019. | 1.3 | 145 |
| 329 | Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. <i>Nature Communications</i> , 2014, 5, 5303. | 5.8 | 109 |
| 330 | PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3212-3220. | 0.8 | 231 |
| 331 | Response to Screening depression during and after pregnancy using the EPDS. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 603-603. | 0.8 | 0 |
| 332 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999. | 5.8 | 105 |
| 333 | Socioeconomic status and depression during and after pregnancy in the Franconian Maternal Health Evaluation Studies (FRAMES). <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 755-763. | 0.8 | 39 |
| 334 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , 2014, 23, 6034-6046. | 1.4 | 12 |
| 335 | Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 747-756. | 5.1 | 810 |
| 336 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014, 16, R51. | 2.2 | 14 |
| 337 | Breast cancer treatment with everolimus and exemestane for ER+ women: Results of the first interim analysis of the noninterventional trial BRAWO.. <i>Journal of Clinical Oncology</i> , 2014, 32, 578-578. | 0.8 | 2 |
| 338 | ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. <i>Gynecologic Oncology</i> , 2013, 131, 8-14. | 0.6 | 55 |
| 339 | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370. | 9.4 | 326 |
| 340 | Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013, 93, 1046-1060. | 2.6 | 98 |
| 341 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384. | 9.4 | 493 |
| 342 | Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 429-440. | 1.1 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 343 | Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 899-908. | 1.1 | 23 |
| 344 | Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2013, 287, 337-344. | 0.8 | 13 |
| 345 | Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. <i>American Journal of Human Genetics</i> , 2013, 92, 489-503. | 2.6 | 201 |
| 346 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398. | 9.4 | 374 |
| 347 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361. | 9.4 | 960 |
| 348 | Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab Results of the randomised GeparQuinto study (GBG 44). <i>European Journal of Cancer</i> , 2013, 49, 2284-2293. | 1.3 | 75 |
| 349 | Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 216-223. | 1.1 | 22 |
| 350 | Evidence of Gene-Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. <i>PLoS Genetics</i> , 2013, 9, e1003284. | 1.5 | 136 |
| 351 | Hormone replacement therapy and prognosis in ovarian cancer patients. <i>European Journal of Cancer Prevention</i> , 2013, 22, 52-58. | 0.6 | 28 |
| 352 | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628. | 5.8 | 144 |
| 353 | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013, 4, 1627. | 5.8 | 98 |
| 354 | The UGT1A6_19_CG genotype is a breast cancer risk factor. <i>Frontiers in Genetics</i> , 2013, 4, 104. | 1.1 | 8 |
| 355 | Common Breast Cancer Susceptibility Variants in <i>LSP1</i> and <i>RAD51L1</i> Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1156-1166. | 1.1 | 101 |
| 356 | Correlates of mammographic density in B-mode ultrasound and real time elastography. <i>European Journal of Cancer Prevention</i> , 2012, 21, 343-349. | 0.6 | 8 |
| 357 | <i>CHEK2</i> *1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer-Specific Death, and Increased Risk of a Second Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 4308-4316. | 0.8 | 162 |
| 358 | The role of genetic breast cancer susceptibility variants as prognostic factors. <i>Human Molecular Genetics</i> , 2012, 21, 3926-3939. | 1.4 | 80 |
| 359 | Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 135-144. | 5.1 | 425 |
| 360 | Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. <i>Lancet Oncology</i> , The, 2012, 13, 385-394. | 5.1 | 753 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 361 | Characterizing mammographic images by using generic texture features. Breast Cancer Research, 2012, 14, R59. | 2.2 | 65 |
| 362 | Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer. Breast Cancer Research and Treatment, 2012, 135, 885-892. | 1.1 | 36 |
| 363 | Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318. | 9.4 | 256 |
| 364 | Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer. New England Journal of Medicine, 2012, 366, 299-309. | 13.9 | 473 |
| 365 | Genetic variants in the tryptophan hydroxylase 2 gene (TPH2) and depression during and after pregnancy. Journal of Psychiatric Research, 2012, 46, 1109-1117. | 1.5 | 43 |
| 366 | Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. Journal of Clinical Oncology, 2012, 30, 1796-1804. | 0.8 | 2,062 |
| 367 | Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis. BMC Cancer, 2012, 12, 597. | 1.1 | 24 |
| 368 | Delivery mode and the course of pre- and postpartum depression. Archives of Gynecology and Obstetrics, 2012, 286, 1407-1412. | 0.8 | 28 |
| 369 | Visual pain mapping in endometriosis. Archives of Gynecology and Obstetrics, 2012, 286, 687-693. | 0.8 | 6 |
| 370 | A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular Genetics, 2012, 21, 5373-5384. | 1.4 | 168 |
| 371 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Human Mutation, 2012, 33, 1123-1132. | 1.1 | 35 |
| 372 | Association of mammographic density with hormone receptors in invasive breast cancers: Results from a case-only study. International Journal of Cancer, 2012, 131, 2643-2649. | 2.3 | 44 |
| 373 | Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 980-987. | 1.1 | 32 |
| 374 | The 5-HTTLPR polymorphism modulates the influence on environmental stressors on peripartum depression symptoms. Journal of Affective Disorders, 2012, 136, 1192-1197. | 2.0 | 60 |
| 375 | Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the mTOR inhibitor RAD001. Biochemical Pharmacology, 2012, 83, 480-488. | 2.0 | 39 |
| 376 | The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant. Breast Cancer Research and Treatment, 2012, 131, 347-350. | 1.1 | 6 |
| 377 | Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380. | 1.1 | 51 |
| 378 | Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor-Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231. | 1.1 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 379 | Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. <i>Journal of the National Cancer Institute</i> , 2011, 103, 250-263. | 3.0 | 596 |
| 380 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 3289-3303. | 1.4 | 152 |
| 381 | A common variant at the TERT-CLPTM1L locus is associated with estrogen receptorâ€“negative breast cancer. <i>Nature Genetics</i> , 2011, 43, 1210-1214. | 9.4 | 279 |
| 382 | Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. <i>BMC Cancer</i> , 2011, 11, 486. | 1.1 | 260 |
| 383 | Mammographic density as a risk factor for breast cancer in a German caseâ€“control study. <i>European Journal of Cancer Prevention</i> , 2011, 20, 1-8. | 0.6 | 53 |
| 384 | Genome-wide association study identifies a common variant associated with risk of endometrial cancer. <i>Nature Genetics</i> , 2011, 43, 451-454. | 9.4 | 141 |
| 385 | Inhibition of hyperalgesia by conditioning electrical stimulation in a human pain model. <i>Pain</i> , 2011, 152, 1298-1303. | 2.0 | 13 |
| 386 | Assessment of breast cancer tumour size using six different methods. <i>European Radiology</i> , 2011, 21, 1180-1187. | 2.3 | 25 |
| 387 | Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 145-156. | 1.1 | 228 |
| 388 | Breast Volumetry Using a Three-Dimensional Surface Assessment Technique. <i>Aesthetic Plastic Surgery</i> , 2011, 35, 847-855. | 0.5 | 50 |
| 389 | Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2011, 128, 2063-2074. | 2.3 | 54 |
| 390 | Quality Assured Health Care in Certified Breast Centers and Improvement of the Prognosis of Breast Cancer Patients. <i>Onkologie</i> , 2011, 34, 362-367. | 1.1 | 106 |
| 391 | Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1638-1648. | 1.1 | 31 |
| 392 | Invasive Breast Cancer: Recognition of Molecular Subtypes. <i>Breast Care</i> , 2011, 6, 258-264. | 0.8 | 38 |
| 393 | 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. <i>Journal of Medical Genetics</i> , 2011, 48, 698-702. | 1.5 | 5 |
| 394 | Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2â€“Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups. <i>Journal of Clinical Oncology</i> , 2011, 29, 3351-3357. | 0.8 | 456 |
| 395 | Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2011, 71, 6240-6249. | 0.4 | 109 |
| 396 | Assessment of mammographic density before and after first full-term pregnancy. <i>European Journal of Cancer Prevention</i> , 2010, 19, 405-412. | 0.6 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 397 | Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. <i>Breast Cancer Research</i> , 2010, 12, R110. | 2.2 | 82 |
| 398 | Quantification of fatty acid ethyl esters (FAEE) and ethyl glucuronide (EtG) in meconium from newborns for detection of alcohol abuse in a maternal health evaluation study. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 2469-2477. | 1.9 | 95 |
| 399 | Pain perception and detailed visual pain mapping in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 105-110. | 1.1 | 24 |
| 400 | Common variants at 19p13 are associated with susceptibility to ovarian cancer. <i>Nature Genetics</i> , 2010, 42, 880-884. | 9.4 | 235 |
| 401 | A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. <i>Nature Genetics</i> , 2010, 42, 874-879. | 9.4 | 321 |
| 402 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010, 42, 885-892. | 9.4 | 309 |
| 403 | Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2024-2031. | 0.8 | 487 |
| 404 | Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2015-2023. | 0.8 | 194 |
| 405 | Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptor-negative Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2010, 102, 650-662. | 3.0 | 48 |
| 406 | Two naturally occurring variants of the serotonin receptor gene HTR3C are associated with nausea in pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010, 89, 7-14. | 1.3 | 24 |
| 407 | Association of ESR1 gene tagging SNPs with breast cancer risk. <i>Human Molecular Genetics</i> , 2009, 18, 1131-1139. | 1.4 | 84 |
| 408 | Risk of Estrogen Receptor-positive and -negative Breast Cancer and Single-nucleotide Polymorphism 2q35-rs13387042. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1012-1018. | 3.0 | 99 |
| 409 | Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. <i>Breast</i> , 2009, 18, 135-141. | 0.9 | 76 |
| 410 | Polymorphisms in estrogen metabolism and estrogen pathway genes and the risk of miscarriage. <i>Archives of Gynecology and Obstetrics</i> , 2009, 280, 395-400. | 0.8 | 18 |
| 411 | A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. <i>Nature Genetics</i> , 2009, 41, 996-1000. | 9.4 | 276 |
| 412 | Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1429. | 3.8 | 468 |
| 413 | Role of genetic polymorphisms and ovarian cancer susceptibility. <i>Molecular Oncology</i> , 2009, 3, 171-181. | 2.1 | 69 |
| 414 | Five Polymorphisms and Breast Cancer Risk: Results from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1610-1616. | 1.1 | 57 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 415 | Neurokinin 1 receptor gene polymorphism might be correlated with recurrence rates in endometriosis. <i>Gynecological Endocrinology</i> , 2009, 25, 726-733. | 0.7 | 6 |
| 416 | Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 89-98. | 1.1 | 77 |
| 417 | Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 873-882. | 1.2 | 37 |
| 418 | Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen. <i>International Journal of Cancer</i> , 2008, 123, 2871-2879. | 2.3 | 37 |
| 419 | Correlates of the desire for improved cosmetic results after breast-conserving therapy and mastectomy in breast cancer patients. <i>Breast</i> , 2008, 17, 640-645. | 0.9 | 16 |
| 420 | The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R58. | 2.2 | 95 |
| 421 | Lymphedema in breast cancer survivors: Assessment and information provision in a specialized breast unit. <i>Patient Education and Counseling</i> , 2007, 66, 311-318. | 1.0 | 65 |
| 422 | Influence of mammographic density on the diagnostic accuracy of tumor size assessment and association with breast cancer tumor characteristics. <i>European Journal of Radiology</i> , 2006, 60, 398-404. | 1.2 | 71 |